jenny mollen glp 1 details 'horror movie' side effects of GLP-1 drug: 'Blood everywhere' Jenny Mollen is opening up

We offer free Mounjaro case evaluations

In a November 4, 2024, press release, the company highlighted preliminary DIO model data: "[P]eripherally-restricted nimacimab achieve[d] significant dose-dependent weight loss" and "[p]reliminary data shows that nimacimab achieves desired metabolic outcomes." Three days later, CEO Dhillon reinforced this on an earnings call: "We believe nimacimabs first-in-class profile as a perfectly targeting CB1 inhibitor offers the right combination of efficacy and safety." The Q3 2024 10-Q echoed the theme, touting nimacimab's potential to "positively impact metabolic disorders including obesity." This optimism escalated

Some people explore phentermine versus GLP-1 comparisons, but they are distinct drug classes

This covers your medical history, weight-loss struggles, lifestyle habits, and overall goals

But weight loss alone doesnt account for all of the cardiovascular benefits of GLP-1s